Asthma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Tarus therapeutics, Lanier Biotherapeutics

The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Asthma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Asthma Market.

Some of the key takeaways from the Asthma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Asthma treatment therapies with a considerable amount of success over the years. 
• Asthma companies working in the treatment market are Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others, are developing therapies for the Asthma treatment 

• Emerging Asthma therapies in the different phases of clinical trials are- Research programme: A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others are expected to have a significant impact on the Asthma market in the coming years.   
• In February 2022, Honeywell announced a commercial partnership with AstraZeneca to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (GWP) propellants to treat asthma and chronic obstructive pulmonary disease (COPD)
• In May 2022, The US Food and Drug Administration (FDA) has approved Avillion’s New Drug Application (NDA) for AstraZeneca’s PT027, according to a statement from Avillion LLP. For patients with asthma who are 4 years of age or older, the recommended indication is for the as-needed treatment or prevention of bronchoconstriction as well as for the prevention of exacerbations. In order to evaluate the safety and effectiveness of PT027, AstraZeneca and Avillion conducted studies on which the NDA submission was based.
• In January 2021, A single-center, double-masked, placebo-controlled, crossover Phase II clinical trial was started by Aldeyra Therapeutics to evaluate the safety and effectiveness of ADX-629 in adult patients with moderate asthma brought on by bronchial asthma challenge. Twelve asthmatics who were allergic to cats or house dust mites were randomised to receive either 600 mg of ADX-629 or a placebo twice daily for about a week.
• In January 2020, To compare the effectiveness and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) with a placebo metered-dose inhaler (placebo MDI) on exercise-induced bronchoconstriction (EIB) in adult and adolescent subjects with asthma, Avillion started a multicenter, randomised, double-blind, single-dose, placebo-controlled, 2-period crossover study

Asthma Overview

A persistent condition that affects the airways is asthma. It is characterised by airway inflammation and spasm. The tubes called airways are what bring air into and out of the lungs. The inner walls of the airways swell and hurt if someone has asthma. Inflammation and muscle tension surrounding the tiny airways cause the airways in the lungs to become smaller.

Get a Free Sample PDF Report to know more about Asthma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/asthma-pipeline-insight

Emerging Asthma Drugs Under Different Phases of Clinical Development Include:

• Research programme: A2BR inhibitors: Tarus therapeutics
• LNR 125.38: Lanier Biotherapeutics
• LABP-73: Landos Biopharma
• CM326: KeyMed Biosciences
• RG6314: HoffmanLa-Roche
• KN-002: Kinaset therapeutics
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• SB010: Sterna Biologics
• ADX-629: Aldeyra Therapeutics
• GSK3511294: GlaxoSmithKline
• BGF MDI: AstraZeneca
• PT027: Avillion LLP

Asthma Route of Administration

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Asthma Molecule Type

Asthma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Asthma Pipeline Therapeutics Assessment

• Asthma Assessment by Product Type
• Asthma By Stage and Product Type
• Asthma Assessment by Route of Administration
• Asthma By Stage and Route of Administration
• Asthma Assessment by Molecule Type
• Asthma by Stage and Molecule Type

DelveInsight’s Asthma Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Asthma product details are provided in the report. Download the Asthma pipeline report to learn more about the emerging Asthma therapies

Some of the key companies in the Asthma Therapeutics Market include:

Key companies developing therapies for Asthma are – GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., and others.

Asthma Pipeline Analysis:

The Asthma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
• Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Asthma drugs and therapies

Asthma Pipeline Market Drivers

• Increasing prevalence of asthma worldwide, R&D focus towards developing novel therapies for asthma, increasing healthcare expenditures are some of the important factors that are fueling the Asthma Market.

Asthma Pipeline Market Barriers

• However, high cost of asthma medications, inadequate knowledge/Less awareness in under-emerging economies, lack of effective and proven therapies for asthma and other factors are creating obstacles in the Asthma Market growth.

Scope of Asthma Pipeline Drug Insight    

• Coverage: Global
• Key Asthma Companies: Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others
• Key Asthma Therapies: Research programme: A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others
• Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
• Asthma Market Dynamics: Asthma market drivers and Asthma market barriers 

Request for Sample PDF Report for Asthma Pipeline Assessment and clinical trials

Table of Contents

1. Asthma Report Introduction

2. Asthma Executive Summary

3. Asthma Overview

4. Asthma- Analytical Perspective In-depth Commercial Assessment

5. Asthma Pipeline Therapeutics

6. Asthma Late Stage Products (Phase II/III)

7. Asthma Mid Stage Products (Phase II)

8. Asthma Early Stage Products (Phase I)

9. Asthma Preclinical Stage Products

10. Asthma Therapeutics Assessment

11. Asthma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Asthma Key Companies

14. Asthma Key Products

15. Asthma Unmet Needs

16 . Asthma Market Drivers and Barriers

17. Asthma Future Perspectives and Conclusion

18. Asthma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services